|
Publication
|
Type of study
|
Number of enrolled patients and controls
|
Type of Cancer
|
SA used for treatment
|
Response to treatment-outcome
|
|---|
| | |
Patients
|
Controls
| | | |
|---|
|
Kourumalis 1998[220]
|
RCT
|
28*
|
30#
|
Advanced HCC
|
OCT SC (500 μg/d)
|
↓AFP,↑S, ↑QoL
|
|
Yuen 2002[221]
|
RCT
|
35*
|
35°
|
Advanced HCC
|
OCT LAR (30 mg/28d)
|
None
|
|
Dimitroulopoulos 2007[166]
|
RCT
|
24* (Octreoscan +)
|
30° (Octreoscan +)
|
Advanced HCC
|
OCT LAR (20 to 30 mg/28d)
|
↑S, ↑QoL
|
|
66# (Octreoscan -)
|
|
Becker 2007[223]
|
RCT
|
60*
|
59°
|
Advanced HCC
|
OCT LAR (30 mg/28d)
|
None
|
|
Barbare 2009[224]
|
RCT
|
135*
|
137°
|
Advanced HCC
|
OCT LAR (30 mg/28d)
|
=S, ↓QoL
|
- RCT, Randomized clinical trial.
- AFP, Alpha fetoprotein.
- S, Survival.
- QoL, Quality of life.
- *: treated patients.
- #: untreated patients.
- °: placebo controls.
